Loss of the balance between CD4+Foxp3+ regulatory T cells and CD4+IL17A+ Th17 cells in patients with type 1 diabetes

Human Immunology

Volumn 74, Issue 6, 2013, Pages 701-707

  Ryba Stanisławowska, Monika ^a   Skrzypkowska, Maria ^a   MyŚliwiec, Małgorzata ^a   MyŚliwska, Jolanta ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 17; TRANSCRIPTION FACTOR FOXP3;

ADOLESCENT; ARTICLE; CELL ACTIVITY; CELL CYCLE PROGRESSION; CELL ISOLATION; CELL LINEAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC MICROANGIOPATHY; DISEASE DURATION; DISEASE PREDISPOSITION; HUMAN; HUMAN TISSUE; IMMUNE SYSTEM; INFLAMMATORY CELL; INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH17 CELL;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; DIABETES MELLITUS, TYPE 1; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-17; LYMPHOCYTE COUNT; NEOVASCULARIZATION, PATHOLOGIC; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; YOUNG ADULT;

EID: 84877011245     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.01.024     Document Type: Article

References (43)

1. Roncarolo M.G., Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 2007, 7:585-598.
2. Costantino C.M., Baecher-Allan C.M., Hafler D.A. Human regulatory T cells and autoimmunity. Eur J Immunol 2008, 38:921-924.
3. Homann D., von Herrath M. Regulatory T cells and type 1 diabetes. Clin Immunol 2004, 112:202-209.
4. + regulatory T cells control autoimmunity?. Curr Opin Immunol 2005, 17638-17642.
5. + regulatory T cells in patients with type 1 diabetes from effects mediated by TNF. Cytokine 2011, 55(3):353-361.
6. Cobb D., Smeltz R.B. Regulation of proinflammatory Th17 responses during Trypanosoma cruzi infection by IL-12 family cytokines. J Immunol 2012, 188(8):3766-3773.
7. Cook A. Th17 cells in inflammatory conditions. Rev Diabet Stud 2006, 3(2):72-75.
8. Bradshaw E.M., Raddassi K., Elyaman W., Orban T., Gottlieb P.A., Kent S.C., et al. Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. J Immunol 2009, 183(7):4432-4439.
9. Lee Y.K., Mukasa R., Hatton R.D., Weaver C.T. Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol 2009, 21(3):274-280.
10. Zhang L., Li Y.G., Li Y.H., Qi L., Liu X.G., Yuan C.Z., et al. Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS One 2012, 7(4):e31000.
11. Wilke C.M., Wang L., Wei S., Kryczek I., Huang E., Kao J., et al. Endogenous interleukin-10 constrains Th17 cells in patients with inflammatory bowel disease. J Transl Med 2011, 9:217.
12. Montes M., Zhang X., Berthelot L., Laplaud D.A., Brouard S., Jin J., et al. Oligoclonal myelin-reactive T-cell infiltrates derived from multiple sclerosis lesions are enriched in Th17 cells. Clin Immunol 2009, 130(2):133-144.
13. Korn T., Oukka M., Kuchroo V., Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol 2007, 19(6):362-371.
14. + regulatory T-cells in type 1 diabetes. Diabetes 2007, 56(3):604-612.
15. high regulatory T cells in human autoimmune diabetes. J Autoimmun 2005, 24:55-62.
16. Ryba M., Hak Ł., Zorena K., MyŚliwiec M., MyŚliwska J. Regulatory T lymphocytes expressing L-selectin in children and adolescents with type 1 diabetes mellitus. Pediatr Endocrinol Diabetes Metab 2010, 16:12-16.
17. + Tregs are associated with inflammatory conditions in type 1 diabetic patients. Med Inf 2011, 2011:645643.
18. Kukreja A., Cost G., Marker J., Zhang C., Sun Z., Lin-Su K., et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002, 109:131-140.
19. + T-cells in type 1 diabetes. Diabetes 2005, 54:1407-1414.
20. + T-cells from patients with type 1 diabetes. Diabetes 2005, 54:92-99.
21. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2008, (Suppl. 1):S55-S60.
22. Marwaha A.K., Leung N.J., McMurchy A.N., Levings M.K. TH17 Cells in autoimmunity and immunodeficiency: protective or pathogenic?. Front Immunol 2012, 3:129.
23. Sallusto F., Zielinski C.E., Lanzavecchia A. Human Th17 subsets. Eur J Immunol 2012, 42(9):2215-2220.
24. Kuchroo V.K., Awasthi A. Emerging new roles of Th17 cells. Eur J Immunol 2012, 42(9):2211-2214.
25. Tatoń J. Pathophysiological Background for " shared" diabetological and opthalmological care - what opthalmologist may expect from diabetologist?. Med Metab 2007, 3.
26. Honkanen J., Nieminen J.K., Gao R., Luopajarvi K., Salo H.M., Ilonen J., et al. IL-17 immunity in human type 1 diabetes. J Immunol 2010, 185(3):1959-1967.
27. Marwaha A.K., Crome S.Q., Panagiotopoulos C., Berg K.B., Qin H., Ouyang Q., et al. Cutting edge: increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J Immunol 2010, 185(7):3814-3818.
28. Ferraro A., Socci C., Stabilini A., Valle A., Monti P., Piemonti L., et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 2011, 60(11):2903-2913.
29. Li B., Greene M.I. Special regulatory T-cell review: FOXP3 biochemistry in regulatory T cells-how diverse signals regulate suppression. Immunology 2008, 123(1):17-19.
30. + regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 2009, 326(5955):986-991.
31. Ichiyama K., Yoshida H., Wakabayashi Y., Chinen T., Saeki K., Nakaya M., et al. Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat. J Biol Chem 2008, 283(25):17003-17008.
32. high T regulatory cells. Blood 2006, 108:253-261.
33. Beriou G., Constantino C.M., Ashley C.W., Yang L., Kuchroo V.K., Baecher-Allan C., et al. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 2009, 113(18):4240-4249.
34. Croxford A.L., Mair F., Becher B. IL-23: one cytokine in control of autoimmunity. Eur J Immunol 2012, 42(9):2263-2273.
35. Lee Y., Awasthi A., Yosef N., Quintana F.J., Xiao S., Peters A., et al. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol 2012, 10:991-999.
36. + regulatory T cells in humans. Proc Natl Acad Sci USA 2009, 106(12):4793-4798.
37. Antonetti D.A., Barber A.J., Bronson S.K., Freeman W.M., Gardner T.W., Jefferson L.S., et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006, 55(9):2401-2411.
38. Shen H., Xia L., Lu J., Xiao W. Infliximab reduces the frequency of interleukin 17-producing cells and the amounts of interleukin 17 in patients with rheumatoid arthritis. J Invest Med 2010, 58:905-908.
39. Lövestam-Adrian M., Agardh C.D., Torffvit O., Agardh E. Diabetic retinopathy, visual acuity, and medical risk indicators: a continuous 10-year follow-up study in Type 1 diabetic patients under routine care. J Diabetes Complications 2001, 15(6):287-294.
40. Nareika A., Im Y.B., Game B.A., Slate E.H., Sanders J.J., London S.D., et al. High glucose enhances lipopolysaccharide-stimulated CD14 expression in U937 mononuclear cells by increasing nuclear factor kappaB and AP-1 activities. J Endocrinol 2008, 196:45-55.
41. Bao W., Min D., Twigg S.M., Shackel N.A., Warner F.J., Yue D.K., et al. Monocyte CD147 is induced by advanced glycation end products and high glucose concentration: possible role in diabetic complications. Am J Physiol Cell Physiol 2010, 299(5):C1212-C1219.
42. Yan S.F., Ramasamy R., Schmidt A.M. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 2008, 4(5):285-293.
43. Ramasamy R., Yan S.F., Schmidt A.M. The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vasc Pharmacol 2012, 57(5-6):160-167.